ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

Senate Passes Biomedical Research Extension; Could Go to President before Congress Recesses

July 26, 1985

The FY 1984 Bypass Budget: How NCI Would Spend the Money

July 9, 1982

Army Breast Cancer Research Program Seeks Proposals

March 28, 1997

Funding Opportunity: NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators

October 3, 2014

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

Imbruvica Improves PFS, OS In Phase III CLL Study

December 26, 2014